Icon

VIEKIRA XR (nda208624)- (EQ 200MG BASE;8.33MG;50MG;33.33MG)

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ABBVIE
EQ 200MG BASE;8.33MG;50MG;33.33MG
No No
2035-Jan-02 2019-Dec-19
None None
None No
VIEKIRA XR includes dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor, ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, and ritonavir, a CYP3A inhibitor and is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV): • genotype 1b infection without cirrhosis or with compensated cirrhosis • genotype 1a infection without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 200MG BASE;8.33MG;50MG;33.33MG ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.